Cargando…

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial

OBJECTIVE: To determine the safety and therapeutic effects of nimotuzumab (h-R3) combined with radiotherapy in esophageal cancer. METHODS: This Phase II clinical trial involved 42 patients with stage II (inoperable or refused surgery) to stage IV (supraclavicular lymph node metastasis only) esophage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Jun, E, Mingyan, Wu, Gang, Zhao, Lujun, Li, Xia, Xiu, Xia, Li, Ning, Chen, Bo, Hui, Zhouguang, Lv, Jima, Fang, Hui, Tang, Yu, Bi, Nan, Wang, Wenqing, Zhai, Yirui, Li, Tao, Chen, Dongfu, Zou, Shuangmei, Lu, Ning, Perez-Rodríguez, Rolando, Zheng, Junqi, Wang, Luhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825695/ https://www.ncbi.nlm.nih.gov/pubmed/24235844 http://dx.doi.org/10.2147/OTT.S50945

Ejemplares similares

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial
por: Yang, Xu, et al.
Publicado: (2021)

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
por: Zhang, Tao, et al.
Publicado: (2020)

Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution
por: Fan, Chengcheng, et al.
Publicado: (2013)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
por: Xu, Kunpeng, et al.
Publicado: (2021)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
por: Yang, Yufan, et al.
Publicado: (2021)

A Single Center Analysis of Thymic Neuroendocrine Tumors †
por: Zhai, Yirui, et al.
Publicado: (2022)

Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy
por: Wang, Wenhui, et al.
Publicado: (2019)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution
por: Wang, Jianyang, et al.
Publicado: (2015)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcome
por: Men, Yu, et al.
Publicado: (2022)

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
por: Yang, Siran, et al.
Publicado: (2022)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study
por: Wang, Daquan, et al.
Publicado: (2019)

Enhanced prediction of postoperative radiotherapy‐induced esophagitis in non‐small cell lung cancer: Dosiomic model development in a real‐world cohort and validation in the PORT‐C randomized controlled trial
por: Ma, Zeliang, et al.
Publicado: (2023)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
por: Hui, Zhouguang, et al.
Publicado: (2021)

The effect of image-guided radiation therapy on the margin between the clinical target volume and planning target volume in lung cancer
por: Liang, Jun, et al.
Publicado: (2014)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018)

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
por: Bi, Nan, et al.
Publicado: (2020)

Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy
por: Fan, Chengcheng, et al.
Publicado: (2013)

Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial
por: Bi, Nan, et al.
Publicado: (2019)

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
por: Wang, Chunyu, et al.
Publicado: (2015)

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non‐small cell lung cancer
por: Wang, Jingbo, et al.
Publicado: (2015)

Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases
por: Wu, Linfang, et al.
Publicado: (2022)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Complete remission after hypofractionated radiotherapy for a patient with inoperable adenoid cystic carcinoma of bronchus: A case report
por: Wang, Daquan, et al.
Publicado: (2018)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

CHST15 promotes the proliferation of TE-1 cells via multiple pathways in esophageal cancer
por: Wang, Xin, et al.
Publicado: (2020)

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
por: Li, Chen, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
por: Li, Chen, et al.
Publicado: (2021)

Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation
por: Ma, Zeliang, et al.
Publicado: (2023)

The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030
por: Zhai, Yirui, et al.
Publicado: (2022)

Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma
por: Zhai, Yirui, et al.
Publicado: (2022)

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells
por: YANG, XIAOYU, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rp1ei6jdmbemr2r6s3t7v7d712